Concurrent chemoradiotherapy with nedaplatin plus paclitaxel or fluorouracil for locoregionally advanced nasopharyngeal carcinoma: Survival and toxicity

Abstract Background The purpose of this study was to review the survival and toxicity in patients with locoregionally advanced nasopharyngeal carcinoma (NPC) treated with intensity‐modulated radiation therapy (IMRT) and concurrent nedaplatin plus paclitaxel or fluorouracil (NP or NF). Methods A total of 155 patients with locoregionally advanced NPC seen at our institution between January 2008 and December 2010 were retrospectively reviewed. Seventy‐nine cases (51%) were treated with IMRT and concurrent NP chemotherapy, and 76 cases (49%) were treated with IMRT and concurrent NF regimen. Survival and toxicity were reported. Results The 3‐year locoregional relapse‐free survival, distant metastasis–free survival, progression‐free survival (PFS), and overall survival (OS) rates were 90.3% and 87.8%, 79.7% and 81.1%, 77.3% and 71.1%, and 81.6% and 83.7% for the NF and NP group, respectively. The results were comparable to that of the cisplatin‐based regimens. Acute and late toxicities were acceptable. Conclusion IMRT with concurrent nedaplatin‐based chemotherapy achieved comparable survival with acceptable toxicity to those of the cisplatin‐based regimens in the treatment of locoregionally advanced NPC. © 2014 Wiley Periodicals, Inc. Head Neck , 36: 1474–1480, 2014